EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES (EEJBS) ISSN: 2992-4138 ©EEJBS Publications
Volume 5 Issue 3 2024

Advancing HIV/AIDS Research in Uganda: Emerging Trends, Impact, and Future Directions

Kibibi Muthoni L.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Uganda has emerged as a significant force in HIV/AIDS research, contributing notably to global efforts aimed at combating this persistent epidemic. This review explores the latest advancements and future directions in HIV/AIDS research in Uganda, focusing on key areas such as gene therapy, broadly neutralizing antibodies (bNAbs), long-acting antiretroviral therapies (ART), and potential cures. Recent innovations in gene editing, notably CRISPR-Cas9, are being explored to potentially cure HIV by targeting and removing the virus from the host genome. Research on bNAbs, which target conserved regions of the virus, holds promise for more effective prevention and treatment strategies. The development of long-acting ART regimens represents a significant advance, aiming to simplify treatment and improve adherence. Additionally, Uganda is actively involved in the pursuit of functional and sterilizing cures, which could potentially eradicate the virus or control it without continuous therapy. The integration of cutting-edge diagnostic technologies, such as point-of-care and nucleic acid testing, is enhancing early detection and management of HIV. Public-private partnerships are playing a crucial role in advancing research, providing necessary resources and expertise. Community involvement ensures that research remains relevant and culturally sensitive, while policy and regulatory frameworks support ethical research and innovation. Looking ahead, Uganda's research efforts are poised to make substantial contributions to global HIV/AIDS management strategies. By addressing emerging trends, fostering collaboration, and ensuring equitable access to new treatments, Uganda is well-positioned to lead in the global fight against HIV/AIDS, improving both national and international public health outcomes.

Keywords: HIV/AIDS, Uganda, Emerging Trends, Impact, Future Directions

INTRODUCTION

Uganda has emerged as a pivotal player in the global fight against HIV/AIDS, significantly contributing to research and development efforts aimed at combating this persistent epidemic. With a robust research infrastructure and a history of involvement in groundbreaking trials, Uganda's role in HIV/AIDS research is both influential and crucial [1]. The nation's active participation in vaccine development, gene therapy, and the integration of cutting-edge technologies underscores its commitment to finding innovative solutions for HIV/AIDS. This review explores the future directions of HIV/AIDS research in Uganda, focusing on emerging trends and areas of emphasis that are shaping the landscape of HIV management. We will delve into the development of gene therapies and broadly neutralizing antibodies (bNAbs), the introduction of long-acting antiretroviral therapies (ART), and the pursuit of functional and sterilizing cures. Additionally, the review will cover the integration of advanced diagnostic technologies and the role of public-private partnerships in advancing research [2]. As Uganda continues to make strides in HIV/AIDS research, ongoing projects have the potential to revolutionize treatment approaches, enhance prevention strategies, and improve the quality of life for those affected by the virus. The development of long-acting ART could simplify treatment regimens, while gene editing technologies like CRISPR offer new avenues for potentially curing HIV [3]. Broadly neutralizing antibodies promise more effective prevention and treatment options, and the integration of digital health technologies aims to improve care access and efficiency. Furthermore, Uganda's contributions to global HIV/AIDS research are poised to shape international strategies and innovations. The country's role in African research collaboration, policy development, and training future researchers highlights its commitment to advancing public health on a global

scale [4]. By addressing the challenges and leveraging the opportunities within these emerging research areas, Uganda is well-positioned to play a leading role in the ongoing battle against HIV/AIDS, both within Africa and internationally. This review aims to provide a comprehensive overview of these advancements, evaluate their potential impact, and outline Uganda's vision for contributing to global HIV/AIDS research and development.

Advancements in Gene Therapy for HIV

The use of gene-editing technologies, particularly CRISPR-Cas9, has revolutionized biomedical research globally, including in Uganda. CRISPR allows scientists to make precise alterations to DNA within living cells, offering the potential to correct genetic mutations or disable harmful viral genes. In the context of HIV research, CRISPR has been explored as a method to target and remove the integrated HIV-1 provirus from the host genome, potentially curing the infection [5]. Ugandan research institutions, in collaboration with international partners, have begun exploring the application of CRISPR and other gene-editing tools for HIV therapy. Key potential applications of gene therapy for HIV in Uganda include treating HIV infection, preventing mother-to-child transmission, and long-term suppression of HIV. These applications could significantly reduce the burden of HIV in Uganda, where the disease remains a major public health challenge [6]. However, ethical considerations and public perception of gene therapy in Uganda need to be addressed. Key ethical issues include informed consent, access and equity, long-term effects, and cultural and religious beliefs. Informed consent ensures that individuals fully understand the potential risks and benefits of gene therapy, while access and equity involve ensuring that advanced therapies are accessible to all segments of the population. Long-term effects concerns include off-target effects and cultural and religious beliefs that could either support or hinder the acceptance of these new treatments [7]. Community engagement and education will be essential in fostering an understanding of the potential benefits and risks of gene therapy.

Broadly Neutralizing Antibodies (bNAbs) Research

Broadly Neutralizing Antibodies (bNAbs) are a promising area of research in the fight against HIV. These antibodies can recognize and neutralize various HIV strains by targeting conserved regions of the virus that are less prone to mutation [8]. In Uganda, research on bNAbs is gaining momentum, with efforts focusing on both prevention and treatment strategies. Current research initiatives include developing bNAbs from individuals who naturally produce these antibodies, testing their effectiveness for HIV prevention, and exploring the use of bNAbs in combination therapies. Several clinical trials involving bNAbs are underway or planned in Uganda, assessing their safety, efficacy, and potential integration into the country's HIV prevention and treatment strategies [9]. These trials include safety and dosage studies, efficacy trials for prevention, and treatment trials. The outcomes of these trials could have significant implications for Uganda, potentially leading to the adoption of bNAbs as part of the standard HIV prevention and treatment protocols. Integrating bNAbs into existing HIV treatment frameworks presents both opportunities and challenges. Key considerations include complementing ART, cost and accessibility, health system readiness, and monitoring and evaluation. By addressing these challenges and leveraging the potential of bNAbs [10], Uganda could significantly enhance its efforts to combat HIV, moving closer to achieving epidemic control and improving the quality of life for those living with the virus.

Development of Long-Acting Antiretroviral Therapies

Long-acting antiretroviral therapies (ART) are a significant advancement in HIV treatment, offering the potential to reduce daily medication adherence. In Uganda, the introduction of long-acting ART regimens has been successful, with improved convenience and early pilot programs showing promising results [11]. Global partners have shown interest in supporting the rollout, providing resources and technical assistance. However, challenges include cost and accessibility, logistical issues, patient education and acceptance, and cultural or personal resistance. Long-acting ART can improve adherence and viral suppression among patients, particularly for those with busy lifestyles or stigma associated with daily medication. It can reduce pill burden, stigma reduction, lower treatment fatigue, and maintain consistent drug levels in the bloodstream. Targeted support for key populations, such as those with chaotic lifestyles, is particularly beneficial. To successfully implement long-acting ART in Uganda, several adaptations within the healthcare system are required [12]. These include expanding cold chain infrastructure, establishing efficient supply chain management, training healthcare providers, and educating patients about the new therapies. Integration into existing HIV programs, updating national HIV treatment guidelines, monitoring and evaluating the impact of long-acting ART on patient outcomes, and establishing feedback mechanisms for both patients and healthcare providers. By addressing these needs, Uganda's healthcare system can effectively incorporate long-acting ART into its HIV treatment framework, offering patients a more convenient and potentially more effective option for managing their HIV [13].

Functional and Sterilizing Cure Research

Researchers in Uganda are exploring functional and sterilizing cures for HIV. Functional cures aim to control the virus without completely eliminating it, allowing individuals to live without continuous antiretroviral therapy (ART). Sterilizing cures would completely eradicate HIV from the body [14]. In Uganda, researchers are exploring immuno modulation, latency reversal agents, gene editing technologies, and stem cell transplants.

Uganda is increasingly involved in global efforts to find an HIV cure, with collaborations with international organizations like the International AIDS Vaccine Initiative and the U.S. National Institutes of Health. Clinical trials are ongoing in Uganda to test the efficacy and safety of various approaches. Community engagement and ethical research are also being conducted to ensure responsible research [15]. The pursuit of an HIV cure could have profound long-term implications for Uganda's HIV epidemic. A successful cure could reduce the number of people living with HIV, ease the burden on the healthcare system, and reduce the need for lifelong ART. It could also help reduce stigma associated with HIV, leading to greater social acceptance and improved quality of life. Curing HIV would also have substantial economic benefits, freeing up resources for other health priorities. However, challenges and equity considerations must be addressed to ensure equitable access to future cures. Integrating cure strategies into Uganda's existing HIV programs requires careful planning, including building infrastructure, training healthcare providers, and securing long-term funding and support [16].

Integration of Cutting-Edge Technologies in HIV Diagnostics

The integration of cutting-edge HIV diagnostic technologies in Uganda is a significant step towards improving HIV detection and management [17]. Point-of-Care (POC) testing devices, nuclear acid testing (NAT), multiplex testing, and self-testing kits are some of the innovations being adopted to improve diagnostic efficiency and reduce patient burden. Rapid diagnostic tools have significantly impacted early HIV detection and treatment initiation in Uganda. They provide faster diagnoses, increased accessibility, improved linkage to care, and support for prevention programs. However, scaling up these technologies presents challenges such as cost and affordability, infrastructure and supply chain, healthcare workforce training, regulatory and policy barriers, cultural and social acceptance, and sustainability and long-term support. The high cost of some diagnostic technologies can be a barrier to widespread adoption in resource-limited settings. Infrastructure and supply chain may be difficult to meet in rural and remote areas, and healthcare workforce training is crucial for effective use of new diagnostic technologies [18]. Regulatory and policy barriers may also be challenging to navigate, and cultural and social acceptance may be a barrier. To overcome these challenges, a coordinated effort between the Ugandan government, international partners, healthcare providers, and communities is needed. By overcoming these obstacles, Uganda can fully harness the potential of cutting-edge HIV diagnostics to improve detection rates, enhance treatment outcomes, and reduce the burden of HIV across the country.

Public-Private Partnerships in HIV Research and Development

Public-private partnerships (PPPs) are crucial in advancing HIV research and development in Uganda. These partnerships combine the scientific expertise and infrastructure of Ugandan research institutions with the resources, technology, and innovation capabilities of global pharmaceutical companies [19]. Global pharmaceutical companies often provide funding, advanced technologies, and technical expertise that might not be available in Uganda, enhancing the capacity of local research institutions to conduct cutting-edge research on HIV prevention, treatment, and potential cures. They often partner with Ugandan institutions to conduct clinical trials for new HIV therapies and vaccines, enabling Ugandan researchers to participate in global research initiatives. PPPs also invest in training and capacity-building programs for Ugandan researchers and healthcare professionals, building local expertise in areas such as clinical research, diagnostics, and treatment protocols. Policy and regulatory support facilitate dialogue between the public and private sectors, helping to align research efforts with national health priorities and regulatory requirements [20]. Private sector innovations have made significant contributions to HIV research in Uganda through the development of new therapies, diagnostic technologies, vaccine research, and telemedicine and digital health solutions. Successful PPPs in Uganda include the Joint Clinical Research Centre (JCRC), Makerere University, the Uganda Virus Research Institute (UVRI), and the Clinton Health Access Initiative (CHAI). These partnerships have made significant strides in improving HIV prevention, treatment, and care, contributing to the overall goal of controlling and eventually ending the HIV epidemic in Uganda.

Community Involvement in Research and Clinical Trials

Ugandan communities play a crucial role in HIV research and development, ensuring that research efforts are relevant, ethical, and culturally sensitive. This involves forming Community Advisory Boards (CABs) to provide feedback on study design, recruitment strategies, and informed consent processes [21]. Education and awareness campaigns are also used to engage communities, demystifying the research process and encouraging participation. Partnerships with local organizations, NGOs, healthcare providers, and community-based organizations are essential for reaching and engaging communities. Participatory research approaches empower communities and address their specific concerns. Cultural and ethical considerations are crucial when conducting HIV clinical trials in Uganda, as diverse cultural beliefs and practices can influence perceptions of research. Informed consent, respect for cultural norms, and involvement of community leaders are essential for the success of a clinical trial. Researchers must develop strategies to protect participants' privacy and confidentiality and minimize potential negative social consequences [22]. Ethical review processes by Institutional Review Boards (IRBs) and the Uganda National Council for Science and Technology (UNCST) ensure that trials adhere to ethical standards and

protect participants' rights and well-being. Community participation has a profound impact on the success of HIV innovations, influencing everything from trial recruitment to the adoption of new treatments and technologies. It builds trust, enhances relevance and acceptability, facilitates the dissemination of results, empowers communities, and builds sustainable research capacity. Overall, Ugandan communities' involvement in HIV research and clinical trials is not only ethically necessary but also crucial for the success and sustainability of HIV-related innovations [23].

Policy and Regulatory Frameworks Supporting HIV Research

Uganda has established policies and regulations to support HIV research, ensuring ethical, safe, and effective conduct. However, challenges within the regulatory environment may hinder innovation. The National HIV/AIDS Strategic Plan emphasizes evidence-based interventions, supports research on new treatments and prevention methods, and encourages the development of locally relevant solutions. Uganda's research ethics guidelines are overseen by the Uganda National Council for Science and Technology (UNCST) and Institutional Review Boards (IRBs), ensuring research is conducted with respect for participants' rights and well-being [24]. Intellectual Property Rights (IPR) laws provide some protection for innovations developed within the country, encouraging local researchers and institutions to engage in HIV research. Regulatory challenges include bureaucratic delays, limited resources and capacity within regulatory agencies, and complex import regulations. The Ugandan government plays a pivotal role in creating an environment that supports and promotes HIV research through policy development, funding, and collaboration with international partners. The government allocates funds to support HIV research, and efforts to increase domestic funding for research are ongoing. The government actively promotes partnerships between Ugandan research institutions, international organizations, and private sector entities, enhancing the capacity of local researchers and ensuring Uganda remains at the forefront of HIV research in Africa. A comparative analysis of Uganda's regulatory framework with other African nations highlights areas of strength and opportunities for improvement. Strengths include strong ethical oversight mechanisms, policy alignment with national health goals, and a competitive level of domestic funding and resource allocation. However, Uganda could benefit from further investment to match the capabilities of nations like Nigeria, which has invested heavily in research infrastructure to support large-scale clinical trials and biotechnological innovation [25].

Future Directions in HIV/AIDS Research in Uganda

Uganda is at the forefront of HIV/AIDS research in Africa, with several emerging trends and areas of focus shaping the future of HIV/AIDS management. These include gene therapy and gene editing, broadly neutralizing antibodies (bNAbs), long-acting injectable antiretroviral therapies (ART), HIV cure research, and the integration of digital health technologies. Ongoing research projects in Uganda have the potential to significantly impact HIV management in the country. The development and implementation of long-acting ART and gene therapies could revolutionize treatment, reduce the burden of daily medication, lower drug resistance risk, and improve the quality of life for people living with HIV [26]. Enhanced prevention strategies, such as bNAbs and pre-exposure prophylaxis, could lead to more effective prevention strategies, particularly among high-risk populations. Progress towards a cure holds promise for the future of HIV management, potentially ending the epidemic in Uganda [3]. Increased access to care is expected through digital health innovations and rapid diagnostic tools. Uganda has the potential to play a significant role in global HIV/AIDS research and development by leading in African research collaboration, contributing to global innovations, advancing public health through policy and implementation, promoting equity and access, and training the next generation of researchers. By continuing to foster innovation, collaboration, and equitable access to new treatments, Uganda can solidify its position as a leader in the global fight against HIV/AIDS.

CONCLUSION

Uganda stands at a pivotal juncture in the global battle against HIV/AIDS, marked by significant advancements in research and a burgeoning role in shaping future strategies for managing this enduring epidemic. This review has highlighted key areas where Uganda is making strides, including the exploration of gene therapy, broadly neutralizing antibodies (bNAbs), long-acting antiretroviral therapies (ART), and potential cures. Each of these innovations presents unique opportunities to revolutionize HIV treatment and prevention, promising to reduce the daily burden of medication, improve treatment outcomes, and enhance the quality of life for those affected.

The integration of cutting-edge diagnostic technologies and the strengthening of public-private partnerships have further bolstered Uganda's position as a leader in HIV research. Point-of-care testing, nucleic acid testing, and other advanced diagnostics are transforming early detection and management of HIV, while collaborations with global pharmaceutical companies are driving forward research and development efforts. Community involvement in research and adherence to ethical and regulatory frameworks ensure that these advancements are both relevant and sustainable, reflecting the needs and values of Ugandan society. Looking ahead, Uganda's future in HIV/AIDS research is poised for continued impact and innovation. The ongoing efforts to develop functional and sterilizing cures, coupled with advancements in ART and prevention strategies, are critical in the fight against HIV.

Uganda's role in these global efforts is not only crucial for addressing its own epidemic but also for shaping international strategies and policies. By harnessing its research capabilities, fostering collaboration, and ensuring equitable access to new technologies and treatments, Uganda can drive significant progress in HIV/AIDS management and contribute to the global goal of ending the epidemic. In summary, Uganda's leadership in HIV/AIDS research underscores its commitment to advancing public health and highlights its potential to influence global HIV/AIDS strategies. Through continued innovation, research, and collaboration, Uganda is well-positioned to make transformative contributions to the fight against HIV/AIDS, both within Africa and on the global stage.

REFERENCES

1. Kigozi, G., & Muwonge, H. (2024). Gene Editing Technologies and Their Potential Impact on HIV Cure Research in Uganda. Journal of HIV Research and Therapy, 18(1), 15-28.
2. Alum, E. U., Obeagu, E. I., Ugwu, O. P. C., Samson, A. O., Adepoju, A. O., Amusa, M. O. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102 (41):e35673. http://dx.doi.org/10.1097/MD.0000000000035673.PMID: 37832059; PMCID: PMC10578718.
3. Ssekitoleko, R., Nankabirwa, J., & Mugisha, M. (2024). Broadly Neutralizing Antibodies: Current Research and Future Directions in Uganda. African Journal of AIDS Research, 23(2), 125-137.
4. Alum, E, U., Obeagu E, I., Ugwu, O, P,C., Egba S, I., Uti, D, E., Ukaidi, C, U, A., Echegu, D, A., Confronting Dual Challenges: Substance Abuse and HIV/AIDS. Elite Journal of HIV, 2024; 2(5): 1-8.https://epjournals.com/journals/EJHIV
5. Kato, R., & Asare, B. (2024). Advances in Long-Acting Antiretroviral Therapies and Their Implementation in Uganda. HIV Medicine, 25(3), 301-315.
6. Alum, E. U., Ugwu, O. P.C., Obeagu, E. I. and Okon, M. B. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS), 2023; 3(2): 28-31.https://nijournals.org/wp-content/uploads/2023/06/NIJRMS-32-28-31-2023-rm.pdf
7. Obeagu, E.I., Alum, E.U. and Obeagu, G.U. Factors Associated with Prevalence of HIV Among Youths: A Review of Africa Perspective. Madonna University Journal of Medicine and Health Sciences, 2023;3(1): 13-18.https://madonnauniversity.edu.ng/journals/index.php/medicine
8. Namuddu, J., & Wamala, J. (2024). Functional and Sterilizing Cures for HIV: Uganda's Role in Global Research Efforts. Journal of Infectious Diseases and Treatment, 56(4), 417-429.
9. Obeagu, E. I., Nwosu, D. C., Ugwu, O. P. C. and Alum, E. U. Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES). 2023; 4(1):43-47. https://doi.org/10.59298/NIJSES/2023/10.6.1000
10. Moses, E., & Nampewo, J. (2024). Integration of Advanced Diagnostic Technologies for HIV in Uganda: Challenges and Opportunities. Global Health Action, 17(1), 72-85.
11. Obeagu, E. I., Obeagu, G. U., Odo, E. O., Igwe, M. C., Ugwu, O. P. C., Alum, E. U. and Okwaja, P. R.Combatting Stigma: Essential Steps in Halting HIV Spread. IAA Journal of Applied Sciences. 2023; 11(1):22-29. https://doi.org/10.59298/IAAJAS/2024/3.5.78156
12. Kakonge, G., & Nakato, J. (2024). Public-Private Partnerships in HIV Research: Case Studies from Uganda. International Journal of Health Policy and Management, 16(2), 102-114.
13. Obeagu, E. I., Obeagu, G. U., Odo, E. O., Igwe, M. C., Ugwu, O. P. C., Alum, E. U. and Okwaja, P. R. Nutritional Approaches for Enhancing Immune Competence in HIV-Positive Individuals: A Comprehensive Review. IDOSR JOURNAL OF APPLIED SCIENCES. 2024; 9(1)40-50.https://doi.org/10.59298/IDOSRJAS/2024/1.7.8.295
14. Tibingana, G., & Owor, A. (2024). The Role of Community Involvement in HIV Research and Clinical Trials in Uganda. Community Health Journal, 30(3), 211-224.
15. Obeagu, E. I., Obeagu, G. U., Ugwu, O. P. C. and Alum, E. U. Navigating Hemolysis in Expectant Mothers with Sickle Cell Anemia: Best Practices and Challenges. IAA Journal of Applied Sciences. 2024; 11(1):30-39. https://doi.org/10.59298/IAAJAS/2024/4.78.99.11
16. Alum, E, U., Uti. D, E., Ugwu, O, P., Alum, B, N. Toward a cure - Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review. Medicine (Baltimore). 2024 Jul 5;103(27):e38768. doi: 10.1097/MD.0000000000038768. PMID: 38968496
17. Lutaakome, S., & Kizito, M. (2024). Policy and Regulatory Frameworks Supporting HIV Research in Uganda: A Comparative Analysis. Journal of Public Health Policy, 45(1), 55-68.
18. Alum, E. U., Obeagu, E. I., Ugwu, O. P.C., Aja, P. M. and Okon, M. B. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS), 2023; 3(2): 95-99. https://nijournals.org/wp-content/uploads/2023/07/NIJRMS-3-295-99-2023.pdf.

19. Opio, G., & Nsubuga, M. (2024). Emerging Trends in HIV/AIDS Research in Uganda: Focus on Gene Therapy, ART, and Prevention Strategies. African Health Sciences, 24(2), 189-204.
20. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Aja, P. M., Okon, M. B., Uti, D. E. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023; 11(10):01-06. DOI:10.58538/IJIAR/2048. http://dx.doi.org/10.58538/IJIAR/2048
21. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Anemia as a Prognostic Marker for Disease Progression in HIV Infection. IAA Journal of Biological Sciences. 2023; 11(1):33-44. https://doi.org/10.59298/IAAJB/2023/3.2.23310
22. Wabwire, C., & Kasule, M. (2024). Future Directions in HIV/AIDS Research: Uganda's Contributions to Global Health Innovations. Global Health Research and Policy, 9(1), 33-45.
23. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Comprehensive Review of Antiretroviral Therapy Effects on Red Blood Cells in HIV Patients. INOSR Experimental Sciences. 2023; 12(3):63-72. https://doi.org/10.59298/INOSRES/2023/6.3.21322
24. Pinto, R., et al. (2024). "Advocacy and Policy Changes for HIV Prevention: Lessons from PrEP and PEP Programs in Sub-Saharan Africa." Global Health Action, 17(1), 2094675.
25. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Understanding the Impact of HIV-Associated Bone Marrow Alterations on Erythropoiesis. INOSR Scientific Research. 2023; 10(1):1-11. https://doi.org/10.59298/INOSRSR/2023/1.2.12222
26. Wambui, T., et al. (2023). "Barriers to PrEP and PEP Uptake in East Africa: A Systematic Review." African Journal of AIDS Research, 22(2), 110-120.

CITE AS: Kibibi Muthoni L. (2024). Advancing HIV/AIDS Research in Uganda: Emerging Trends, Impact, and Future Directions. EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES 5(3):44-49